Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice

6 Dec 2018

Abstract excerpt

The ubiquitous Epstein-Barr virus (EBV) is the primary cause of infectious mononucleosis and is etiologically linked to the development of several malignancies and autoimmune diseases.EBV has a multifaceted life cycle that comprises virus lytic replication and latency programs.Considering EBV infection holistically, we rationalized that prophylactic EBV vaccines should ideally prime the immune system against...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytomegalovirus and herpesvirus research
Share to Immune Cell Function and Interaction
Share to Viral-associated cancers and disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30521644
DOI: 10.1371/journal.ppat.1007464

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in micePMID 30521644Read ↗

A Virus-Like Particle-Based Epstein-Barr Virus VaccineSemantic proximity Read ↗

Progress in Prophylactic and Therapeutic EBV Vaccine Development Based on Molecular Characteristics of EBV Target AntigensSemantic proximity Read ↗

A cocktail nanovaccine targeting key entry glycoproteins elicits high neutralizing antibody levels against EBV infectionSemantic proximity Read ↗

The Epstein-Barr Virus Major Tegument Protein BNRF1 Is a Common Target of Cytotoxic CD4+T CellsSemantic proximity Read ↗

Developments in virus-like particle-based vaccines for infectious diseases and cancerSemantic proximity Read ↗

A Lymph Node Targeted Adjuvant and Engineered Subunit Vaccine Promotes Potent Immunity to Epstein-Barr Virus in HLA-expressing MiceSemantic proximity Read ↗

The coming of age of virus-like particle vaccinesSemantic proximity Read ↗

Immune regulation in Epstein-Barr virus-associated diseasesSemantic proximity Read ↗

Immunomics: discovering new targets for vaccines and therapeuticsSemantic proximity Read ↗

Eliciting B cell immunity against infectious diseases using nanovaccines.Semantic proximity Read ↗

An Epstein-Barr Virus Mutant Produces Immunogenic Defective Particles Devoid of Viral DNASemantic proximity Read ↗

An insect cell-derived extracellular vesicle-based gB vaccine elicits robust adaptive immune responses against Epstein-Barr virusSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.